On September 15-16 CED's Tech Venture Conference returns to Raleigh, NC. Join over 600 entrepreneurs, venture capital, angel, and strategic investors from around the country. The 2015 conference again will feature presentations from some of the most disruptive and innovative companies from the Southeast.More
Since 2011, CED's Venture Mentoring Service (VMS) has connected over 120 high-growth companies with skilled mentor teams. Entrepreneurs looking for help in setting and achieving critical milestones are encouraged to apply.More
CED's Innovators Report tracks the entrepreneurial activity throughout North Carolina. Using data derived from national databases and CED's extensive network, the Innovators Report provides a semi-annual scorecard on the funding, IPO, acquisition, and overall health of the entrepreneurial community.More
January 13, 2015
This isn't your father's job fair. The best tech companies pitch YOU. The Winter 2015 Big Top Reverse Job Fair will be held this year in the RTP Headquarters located in the middle of Raleigh/Durham/Chapel Hill.
January 20, 2015
The 2015 Kickoff Meetup of NC RIoT will help frame the IoT discussion in North Carolina over the next 12 months, which promises to be a big year for IoT investment and expansion.
March 3, 2015
The CED Life Science Conference enables NC life science entrepreneurs to connect with hundreds of venture capital and strategic investors from around the nation and boasts globally-recognized industry leaders as conference speakers and participants. The 2015 conference will be held at the Raleigh Convention Center.
The Triangle and its companies are #ontherise, leading the next wave of innovation in America’s technology-based economy.
KIYATEC is ushering in a new world of cancer prognostics that use primary tumor cells grown and tested in a more relevant 3D complex tumor microenvironement. We are located within the Institute for Translational Oncology Research (iTOR) at GHS in Greenville, SC where we provide oncology drug response profiling services and are rapidly expanding our predictive clinical diagnostics efforts, initially focusing on ovarian cancer.More